# United States Department of Agriculture Center for Veterinary Biologics Testing Protocol

#### SAM 118

# Supplemental Assay Method for Titration of Pseudorabies Virus in Vaccines

Date: April 4, 2005

Number: VIRSAM0118.02

Supersedes: MVSAM0118.01, Dated October 27, 1998

Standard Requirement: 9 CFR 113.318

Contact: Kenneth A. Eernisse, (515) 663-7857

Peg A. Patterson, (515) 663-7334

Approvals:

/s/Donna M. Gatewood\_\_\_\_\_ Date:\_19APR05\_

Donna M. Gatewood, Section Leader

Virology Section

/s/Richard E. Hill, Jr.\_\_\_\_\_ Date:\_19APR05\_

Richard E. Hill, Jr., Director Policy, Evaluation, and Licensing Center for Veterinary Biologics

/s/Rebecca L.W. Hyde\_\_\_\_\_ Date:\_19APR05\_

Rebecca L.W. Hyde, Section Leader

Quality Assurance

Center for Veterinary Biologics

Vunited States Department of Agriculture
Animal and Plant Health Inspection Service
P. O. Box 844
Ames, IA 50010

Mention of trademark or proprietary product does not constitute a guarantee or warranty of the product by USDA and does not imply its approval to the exclusion of other products that may be suitable.

Supplemental Assay Method for Titration of Pseudorabies Virus in Vaccines
Table of Contents

- 1. Introduction
- 2. Materials
  - 2.1 Equipment/instrumentation
  - 2.2 Reagents/supplies
- 3. Preparation for the test
  - 3.1 Personnel qualifications/training
  - 3.2 Preparation of equipment/instrumentation
  - 3.3 Preparation of reagents/control procedures
  - 3.4 Preparation of the sample
- 4. Performance of the test
- 5. Interpretation of the test results
- 6. Report of test results
- 7. References
- 8. Summary of revisions

#### 1. Introduction

This Supplemental Assay Method (SAM) describes an *in vitro* test method which utilizes viral plaque forming units (PFU) in a cell culture system to titer pseudorabies virus (PRV) in modified-live vaccines.

#### 2. Materials

#### 2.1 Equipment/instrumentation

Equivalent equipment or instrumentation may be substituted for any brand name listed below.

- **2.1.1**  $36^{\circ}\pm 2^{\circ}C$ ,  $5\%\pm 1\%$   $CO_2$ , high humidity incubator (Model 3158, Forma Scientific Inc.)
- 2.1.2 Vortex mixer (Vortex-2 Genie, Model G-560, Scientific Industries Inc.)
- 2.1.3 Blender
- **2.1.4** Micropipettors:  $200-\mu l$  and  $1000-\mu l$  single channel
- 2.1.5 Water bath

#### 2.2 Reagents/supplies

Equivalent reagents or supplies may be substituted for any brand name listed below. All reagents and supplies must be sterile.

- 2.2.1 PRV Reference Virus, Shope strain [available from the Center for Veterinary Biologics (CVB)]
- **2.2.2** Madin-Darby bovine kidney (MDBK) or other permissive cells
- 2.2.3 Minimum Essential Medium (MEM)
  - **2.2.3.1** 9.61 g MEM with Earles salts without bicarbonate
  - **2.2.3.2** 1.1 g sodium bicarbonate (NaHCO<sub>3</sub>)

- 2.2.3.3 Q.S. to 1000 ml with deionized water (DI), adjust pH to 6.8-6.9 with 2N hydrochloric acid (HCl).
- 2.2.3.4 Sterilize through 0.22-µm filter.
- 2.2.3.5 Aseptically add:
  - 1. 10 ml L-glutamine (200 mM)
  - 2. 5 ml lactalbumin hydrolysate or edamine
  - 3. 50 µg/ml gentamicin sulfate
- **2.2.3.6** Store at 2°- 7°C
- 2.2.4 Growth Medium
  - 2.2.4.1 900 ml of MEM
  - **2.2.4.2** Aseptically add 100 ml gamma-irradiated fetal bovine serum (FBS).
  - **2.2.4.3** Store at 2°- 7°C.
- 2.2.5 2X Medium
  - **2.2.5.1** 100 ml 10X MEM with Earles salts without bicarbonate
  - 2.2.5.2 2.2 g sodium bicarbonate
  - 2.2.5.3 340 ml DI
  - 2.2.5.4 Sterilize through 0.22-µm filter.
  - 2.2.5.5 Aseptically add:
    - 1. 50  $\mu$ g/ml gentamicin sulfate
    - 2. 50 ml FBS
  - **2.2.5.6** Store at 2°- 7°C.

- 2.2.6 2% Tragacanth Gum (Trag)
  - **2.2.6.1** 20 g Trag
  - 2.2.6.2 1000 ml DI
  - 2.2.6.3 Mix vigorously small amounts at a time with a blender set on high.
  - 2.2.6.4 Pour 500 ml each into 1000-ml media bottles.
  - **2.2.6.5** Sterilize by autoclaving at 15 psi for 30 minutes.
  - **2.2.6.6** Store at 2°- 7°C
- 2.2.7 Overlay Medium
  - 2.2.7.1 Mix equal volumes of 2X Medium and 2% Trag.
  - **2.2.7.2** Store at 2°- 7°C.
- 2.2.8 70% Ethyl Alcohol
  - **2.2.8.1** 74 ml ethyl alcohol
  - 2.2.8.2 26 ml DI
  - 2.2.8.3 Store at room temperature.
- 2.2.9 Crystal Violet Stain
  - **2.2.9.1** 7.5 g crystal violet
  - 2.2.9.2 50 ml 70% ethyl alcohol
  - 2.2.9.3 Dissolve crystal violet in alcohol.
  - **2.2.9.4** 250 ml formaldehyde
  - **2.2.9.5** Q.S. to 1000 ml with DI, filter through filter paper.
  - 2.2.9.6 Store at room temperature.

- 2.2.10 Tissue culture plates, 6-well
- 2.2.11 12 x 75-mm polystyrene tubes
- 2.2.12 Graduated cylinders, 25-ml, 50-ml, 100-ml, and 250-ml, sterile
- 2.2.13 Serological pipette, 10-ml

# 3. Preparation for the test

# 3.1 Personnel qualifications/training

Personnel must have training in the immunologic basis of virus titration assays, cell culture maintenance, and in the principles of aseptic techniques.

### 3.2 Preparation of equipment/instrumentation

Set the water bath at 36°± 2°C.

#### 3.3 Preparation of reagents/control procedures

# **3.3.1** Two days prior to test performance

Seed 6-well tissue culture plates with MDBK cells, in Growth Medium, at a cell count that will produce a monolayer after 2 days of incubation at 36°± 2°C.

These become the MDBK plates. Growth Medium is changed if excess acidity of the medium is observed as indicated by a change from red to yellow of Growth Medium.

# **3.3.2** On day of test performance

Rapidly thaw a vial of PRV Reference Virus in a water bath at  $36^{\circ}\pm$  2°C. Dilute the virus in 4.5 ml MEM to contain 15-40 PFU/100 µl.

#### 3.4 Preparation of the sample (on day of test performance)

- 3.4.1 Rehydrate a vial of the Test Vaccine by removing the seal and stopper from both the Test Vaccine bottle and the bottle containing the accompanying diluent. Measure the diluent into a sterile graduated cylinder according to the number of doses indicated on the manufacturer's instructions (e.g., for a 50-dose container of 2-ml-per-dose, reconstitute with 100 ml of diluent), and aseptically pour the diluent into the lyophilized bottle of vaccine. Mix by vortexing. Allow to sit for 15 ± 5 minutes at room temperature.
- **3.4.2** Prepare serial tenfold dilutions of test vaccine. Serial tenfold dilutions may be made as follows:
  - **3.4.2.1** Place 4.5 ml of MEM with the pipette into labeled  $12 \times 75$ -mm polystyrene tubes.
  - **3.4.2.2** Pipette 500  $\mu$ l of test vaccine to the  $10^{-1}$  tube, mix by vortexing. Discard pipette tip.
  - **3.4.2.3** Repeat step **3.4.2.2** to the remaining tubes. Continue as needed  $(10^{-2} \text{ to } 10^{-5})$ , transferring 500  $\mu l$  from previous tube to the next dilution.

#### 4. Performance of the test

- 4.1 Decant the Growth Media from MDBK plates.
- 4.2 Pipette 100  $\mu$ l/well from each dilution of test vaccine to 2 wells of a MDBK plate. Mix by gentle swirling.
- 4.3 Pipette 100  $\mu$ l/well of the diluted Reference Virus Control to 2 wells of 1 MDBK plate. Mix by gentle swirling.
- **4.4** Maintain 2 or more wells as uninoculated cell culture controls.
- **4.5** Incubate inoculated plates at  $36^{\circ}\pm\ 2^{\circ}\text{C}$  in a  $\text{CO}_2$  atmosphere for  $60\ \pm\ 10$  minutes for virus adsorption.
- **4.6** Add 3.0 ml/well of warmed (36°) Overlay Medium (see **Section 2.2.7**) to the plates. Discard any unused, warmed Overlay Medium.

- **4.7** Incubate the MDBK plates undisturbed at  $36^{\circ}\pm\ 2^{\circ}\text{C}$  in a  $\text{CO}_2$  atmosphere for 4 days.
- **4.8** At the end of incubation, decant Overlay Medium. Pipette 2 ml of the Crystal Violet Stain (see **Section 2.2.9**) into each well of the plates using the repetitive syringe.
- **4.9** Allow plates to stand at room temperature for  $15 \pm 5$  minutes.
- **4.10** Discard the Crystal Violet Stain down a sink. Wash the cell monolayers by dipping each plate several times in a container of running water from the cold faucet. Allow to air dry.
- 4.11 PFU counting
  - **4.11.1** The PFU are visible as clear, circular areas in the cell monolayer where the cells have been destroyed by the virus.
  - 4.11.2 Count the number of PFU for each well.
    - **4.11.2.1** Average the number of PFU between the duplicate wells for each test vaccine dilution.
    - **4.11.2.2** Average the number of PFU between the 2 wells of the Reference Virus Control wells.
  - **4.11.3** Determine the virus titers and express as PFU/dose. Take the dilution of a test vaccine that contains an average of at least 30 PFUs. Example:

 $Log_{10}$  of plaque count (30) 1.48  $Log_{10}$  of dilution counted (10<sup>-3</sup>) 3.00  $Log_{10}$  of 2-ml dose factor (20) 1.30

Virus titer/dose (total) 5.78

The test vaccine contains  $10^{5.78}$  PFU/2-ml dose.

#### 5. Interpretation of the test results

**5.1** The test is invalid if visible contamination is observed in all dilutions of a Test Vaccine.

- **5.2** For a valid assay, the Reference Virus Control must have an average PFU count between 15-40.
- **5.3** Any test not meeting the criteria of **5.1** and **5.2** is considered a **NO TEST** and may be repeated without prejudice.
- **5.4** One plaque represents a single infective unit whereas the 50% endpoint infective dose (one  $ID_{50}$ ) is statistically equivalent to a theoretical 0.69 of an infective unit. Fifty percent endpoints will be 1.44 times those expressed as PFU/unit of inoculation. Therefore, to express PFU titer as 50% tissue culture infective dose (TCID<sub>50</sub>) titer, multiply the PFU by 1.44 or add 0.16 to the  $log_{10}$  value of the PFU titer. In the example above, the TCID<sub>50</sub> would be 5.78 + 0.16 = 5.94 or  $log_{10}$  TCID<sub>50</sub>/2-ml dose.
- **5.5** If the validity requirements are met and the titer of the vaccine is greater than or equal to the titer contained in the filed outline of production for the product under test, the product is considered **SATISFACTORY**.
- **5.6** If the validity requirements are met but the titer of the Test Vaccine is lower than the required minimum, it must be retested according to 9 CFR 113.8.

#### 6. Report of test results

- **6.1** Test results are reported as the virus titer in  $TCID_{50}/dose$ .
- **6.2** Record all test results on the test record.

# 7. References

- 7.1 Code of Federal Regulations, Title 9, U.S. Government Printing Office, Washington, DC, 2004.
- 7.2 Conrath TB.: Handbook of Microtiter Procedures. 1972 Clinical and Research Applications Laboratory, Cooke Engineering Company, Alexandria, VA.

#### 8. Summary of revisions

This document was revised to clarify the practices currently in use at the Center for Veterinary Biologics and to provide additional detail. While no significant changes were made that impact the outcome of the test, the following changes were made to the document:

- 2.1.7 "Self-refilling syringe" has been removed.
- 2.2.3.2 The amount of sodium bicarbonate (NaHCO<sub>3</sub>) has been changed from 2.2 g to 1.1 g.
- 2.2.3.5/2.2.5.5 Penicillin and streptomycin have been deleted.
- 2.2.12 "10 ml syringe and needles" has been replaced with graduated cylinders.
- 3.4.1 "10 ml syringe and needle" has been deleted. Instructions have been added for reconstituting the test vaccine with accompanying diluent by graduated cylinders
- The refrigeration temperatures have been changed from 4° ± 2°C to 2°- 7°C. This reflects the parameters established and monitored by the Rees system.